Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia
In pediatric acute myeloid leukemia (AML), fusions involving lysine methyltransferase 2A (KMT2A) are considered hallmarks of aggressive AML, for whom the development of targeted specific therapeutic agents to ameliorate classic chemotherapy and obtain a complete eradication of disease is urgent. In...
Saved in:
Main Authors: | Claudia Tregnago (Author), Maddalena Benetton (Author), Ambra Da Ros (Author), Giulia Borella (Author), Giorgia Longo (Author), Katia Polato (Author), Samuela Francescato (Author), Alessandra Biffi (Author), Martina Pigazzi (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Partial Duplication of the 5' Segment of KMT2A Revealed KMT2A-MLLT10 Rearrangement in a Boy with Acute Myeloid Leukemia
by: Hiroko Fukushima, et al.
Published: (2017) -
Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias
by: Bruno A. Lopes, et al.
Published: (2022) -
Dysregulated transcriptional networks in KMT2A- and MLLT10-rearranged T-ALL
by: Huining Kang, et al.
Published: (2018) -
Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)-Gene Rearrangements
by: Alexia Tsakaneli, et al.
Published: (2021) -
A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells
by: Tianming Zhao, et al.
Published: (2023)